JP Patent

JP7613743B2 — 転移性癌および化学療法抵抗性癌の治療のためのテトラヒドロキノリノ誘導体

Assigned to ザ、トラスティーズ オブ プリンストン ユニバーシティ · Expires 2025-01-15 · 1y expired

What this patent protects

Patent listed against Rezlidhia.

Drugs covered by this patent

Patent Metadata

Patent number
JP7613743B2
Jurisdiction
JP
Classification
—
Expires
2025-01-15
Drug substance claim
No
Drug product claim
No
Assignee
ザ、トラスティーズ オブ プリンストン ユニバーシティ
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.